Advances in therapy · 2026
Real-World Adult Height Outcomes in Girls with Central Precocious Puberty Receiving GnRHa Monotherapy or Combined with Growth Hormone: A Cohort Study in China.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Fei, Li Yan, Yang Yu, Gu Wei, Xu Xuan, Wu Haiying, Li Guimei, Yin Xiaoqin, Zhou Shasha, Li Pin
Аннотация
INTRODUCTION: Although gonadotropin-releasing hormone analogs (GnRHa) are the standard treatment for central precocious puberty (CPP), the efficacy of GnRHa monotherapy in older children (around 8 years) and that of combination therapy with recombinant human growth hormone (rhGH) both remain unclear. This study aims to evaluate the real-world efficacy of each regimen.
METHODS: This retrospective cohort study enrolled Chinese girls with CPP. Two groups were formed: GnRHa monotherapy and GnRHa + rhGH combination therapy. Outcomes included adult height gain [AHG, final adult height (FAH) standard deviation score (SDS)- predicted adult height (PAH) SDS]，genetic height gain [GHG, FAH SDS-target height (Tht) SDS], and change in height (FAH SDS - baseline height SDS).
RESULTS: In the GnRHa group, the mean age at treatment initiation was 8.87 ± 0.87 years. After 17.87 months of treatment, the AHG was 1.33 SDS (0.82, 2.00). In the GnRHa + rhGH group, the mean age at treatment initiation was 9.01 ± 0.80 years. After 23.02 months of GnRHa treatment and 14.02 months of rhGH treatment, the group showed significantly greater AHG [1.72 SDS (1.24, 2.59)].
CONCLUSIONS: GnRHa monotherapy initiated after age 8 may still provide meaningful height gains, and adding rhGH is associated with improved FAH in patients with severe baseline height impairment.
METHODS: This retrospective cohort study enrolled Chinese girls with CPP. Two groups were formed: GnRHa monotherapy and GnRHa + rhGH combination therapy. Outcomes included adult height gain [AHG, final adult height (FAH) standard deviation score (SDS)- predicted adult height (PAH) SDS]，genetic height gain [GHG, FAH SDS-target height (Tht) SDS], and change in height (FAH SDS - baseline height SDS).
RESULTS: In the GnRHa group, the mean age at treatment initiation was 8.87 ± 0.87 years. After 17.87 months of treatment, the AHG was 1.33 SDS (0.82, 2.00). In the GnRHa + rhGH group, the mean age at treatment initiation was 9.01 ± 0.80 years. After 23.02 months of GnRHa treatment and 14.02 months of rhGH treatment, the group showed significantly greater AHG [1.72 SDS (1.24, 2.59)].
CONCLUSIONS: GnRHa monotherapy initiated after age 8 may still provide meaningful height gains, and adding rhGH is associated with improved FAH in patients with severe baseline height impairment.